Group items tagged

The Mentored Clinical Research Award (MCRA) for new investigators is funded by a grant from the Parkinson's Disease Foundation (PDF) to the Parkinson Study Group (PSG). The PDF collaborates with the PSG to encourage the professional and scientific development of young investigators on their path to independence. To this end, this grant supports a new investigator for a one year project in patient oriented research in Parkinson's disease (PD) or other parkinsonian disorders. The new investigator works under the mentorship of an experienced investigator. Training should enhance the junior clinical research skills. The research plan should address unmet needs of people living with PD, have the potential for broad application among the PD community, and lead to advances in clinically relevant treatment options.

The Davis Phinney Foundation for Parkinson's seeks to promote tangible tools and practices that improve quality of life for those suffering from Parkinson's disease. Established by the celebrated American cyclist and Olympian Davis Phinney, who was diagnosed with Parkinson's disease in 2000, the foundation supports research dedicated to the impact of exercise, speech, and movement in enhancing the well-being and happiness of those with Parkinson's. To that end, the foundation is accepting Letters of Intent to its 2019 Research Funding Program. Through the program, a total of $50,000 will be awarded in support of research projects, with priority given to those focused on exercise and nutrition. Awards can be used for both research and program costs. Any researcher or program director with an innovative strategy to improve quality of life for those with Parkinson's are eligible to apply.

This Funding Opportunity Announcement (FOA) requests Exploratory Grant (P20) applications for the planning and initiation of collaborative activities to advance Parkinson's Disease (PD) research. The goal of this FOA is to convene new transdisciplinary research consortia and formalize the multi-institutional organizational and investigational structure necessary to resolve an essential challenge in Parkinson's disease (PD) through a subsequent NINDS Udall Center without Walls (CWOW) approach. The most compelling applications will: (i) identify a fundamental PD research priority; (ii) build an exemplary research consortium; (iii) gather supportive preliminary data; and (iv) demonstrate exceptional potential to pursue a targeted strategy to remove a critical impediment blocking advancement of the understanding and treatment of PD. The stated challenge and related research feasibility projects will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the central PD research challenge. To foster the development of innovative research collaborations, this FOA will provide support for new research consortia only; continuation of established projects and teams will not be supported. Proposed consortia must include the optimal combination of specialized expertise required to resolve the stated challenge using a goal-driven approach. The Program Director/Principal Investigator (PD/PI) must be eminently qualified to provide visionary scientific leadership and effective oversight of consortium administrative activities. Participating investigators should be recognized as world-class experts in their fields. Teams must be anchored by at least one PD researcher. To maximize potential for new insights and incorporation of cutting-edge approaches, consortia will actively integrate at least one investigator with primary expertise in another, complementary research area.

The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. A staged approach will be used to first identify and address pre-analytical variables and then incorporate that information into the optimal design for the analysis of 4500 CSF and plasma samples.

The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from the Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data and workflows generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. The proteomics analysis will be staged to include identification of pre-analytical variables, that will inform the optimal handling of 4,500 CSF and plasma samples.

The Parkinson's Disease Digital Biomarker DREAM Challenge is a first of its kind challenge, designed to benchmark methods for the processing of sensor data for development of digital signatures reflective of Parkinson's Disease. Participants will be provided with raw sensor (accelerometer, gyroscope, and magnetometer) time series data recorded during the performance of pre-specified motor tasks, and will be asked to extract data features which are predictive of PD pathology. In contrast to traditional DREAM challenges, this one will focus on feature extraction rather than predictive modeling, and submissions will be evaluated based on their ability to predict disease phenotype using an array of standard machine learning algorithms.